Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals
|
|
- Kelly Whitehead
- 5 years ago
- Views:
Transcription
1 ORIENTATION FOR NEW CLINICAL RESEARCH COORDINATORS Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals
2 Overall Agenda for Orientation Module 1: Introduction to Clinical Research, Education, and IRB Module 2: Informed Consent, Documentation and GCP, and Study Start up Module 3: Contracting, ClinicalTrials.gov, and Drug/ Device Policies, Conflict of Interest Policy Module 4: Recruitment, Preparing Industry & NIH Grant Budgets, Accounting, Billing Coverage Analysis Module 5: Essential Documents, From CDA to Study Close Out
3 ESSENTIAL (REGULATORY) Valorie Buchholz DOCUMENTS Associate Director for Clinical Trial Quality Assurance Office of Clinical Trials
4 Mornings in the Regulatory World
5 What Types of Trials Should Meet GCP Guidelines? FDA Regulated Trials Federally funded (NIH) Trials Requirement as of January, 2017 A quality research site complies with the ICH Good Clinical Practice guidelines, the accepted international ethical and scientific quality standards for designing, conducting, recording, and reporting trials involving human participants. American Society of Clinical Oncology Statement on Minimum Standards and Exemplary Attributes of Clinical Trial Sites; R. Zion et al; Journal of Clinical Oncology; April 7, 2008
6 What are Essential Documents? ICH defines Essential Documents as: the documents which individually and collectively permit the evaluation of the conduct of a trial and the quality of the data produced (ICH GCP E6 (R2) 8.1)
7 GCP Essential Documents Guidance Categorizes documents into 3 sections Defines whether the sponsor, site or both are responsible for maintenance of the documents Reminder If your investigator holds and IND or IDE, he/she also has sponsor responsibilities
8 BEFORE STUDY IS INITIATED: Investigative Site Sponsor/Funding Agency
9 IND trials 1572 Statement of Investigator IDE Trials Investigator Agreement
10 Documentation for Investigators and Sub- Investigators Curriculum Vitae Licensure Certifications Documents qualifications and eligibility to conduct trial Documents eligibility to provide medical supervision of subjects Documents qualifications to perform tasks as delegated GCP 2.8, 4.1.1, 4.1.5
11 AND MORE APPROVAL DOCUMENTS AGREEMENTS Institutional Review Board Regulatory Authorities Protocol Review Committee Institutional Biosafety Committee Scientific Review Committee Site and Sponsor Site and CRO Financial Aspects Disclosure Forms (FDA) GCP 3.4, 4.5.1, 8.2.4, 8.2.9
12 AND MORE Normal Ranges Lab Info CLIA CAP CV of Medical Director GCP
13 JUST A FEW MORE Investigational Product Shipping and Accountability Records Applicable for both Drugs and Devices Procedures for Decoding Blinded Trials used in case of emergency doesn t break blind for others Study Initiation Report Document questions asked during SIV! GCP , , , ,
14 READY, SET, GO! Documents updated during the study UPDATE Laboratory Accreditations (CLIA/CAP) 1572 /Investigator Agreement Only required by FDA if a new protocol is added to the IND and the Investigator is participating OR a new investigator is added Investigator s Brochures Normal values to lab ranges GCP , 8.3.1, 8.3.6
15 Update IRB renewals / modifications Regulatory Authorities Biosafety Committee Protocol Review Committee CV s / Licensures / Certifications for New Investigators GCP
16 ADD LOGS DELEGATIO N OF AUTHORITY LOG / SIGNATURE SHEET SCREENING LOG SUBJECT ENROLL- MENT LOG SUBJECT ID CODE LIST TRAINI NG LOGS Protocol IB Equipment CRF Completio n / Correction RETAI NED BODY FLUID / TISSU E SAMP LES GCP 4.1.5, 4.2.4, ,
17 INCLUDE RELEVANT COMMUNICATIO NS Letters Memos to File Meeting Notes Telephone Calls GCP
18 SAFETY SERIOUS ADVERSE EVENTS Report to sponsor and IRB UNANTICIPATED / UNEXPECTED ADVERSE EVENTS Report to Sponsor and IRB SAFETY INFORMATION / REPORTS Sponsors Notify Sites
19 STUDY COMPLETION Logs Investigational Product Accountability Subject Identification Code Final Close-out monitoring report Includes where site documents will be stored Termination of study with IRB Clinical Study Report
20 Inspections and Essential Documents Sponsors and other regulatory agencies look to these documents as part of their processes to confirm the validity of the conduct of the trial and the data collected
21 Record Retention Requirements Depends on the Type of Trial FDA: 21CFR (IND) OR 21CFR (IDE) Contracts with Funding Source Institutional Policies: (see Section 6 Grants and Research Records) Pediatric Studies UNC Healthcare Policy? GCP
22 TAKE AWAY POINTS Organized Consistent
23 For Additional Information article/efficacy-guidelines.html guidancecomplianceregulatoryinformation/guidances/ucm pdf
24
25 FROM CDA TO STUDY CLOSURE Panel Members: Christine Nelson Val Buchholz
26 Objectives Review the steps for successful clinical trial implementation beginning with first sponsor contact through study closure
27 So it begins
28 Site Survey Site information form Site Qualification form Site Feasibility form Sponsors and CROs track turn around times
29
30 CDA CDA must be submitted via CRMS Cannot be signed by PI Quick turn around Not every CDA results in receiving a protocol Sponsors and CROs track turn around times
31
32 CRMS Protocol final or draft? May just send protocol until you are selected as a site May send someone out to do site qualification visit Draft ICF Draft CTA Draft Budget Investigator brochure Pharmacy manual Lab manual
33
34 Feasibility Conduct a preliminary feasibility assessment Read the draft ICF Read the protocol Potential enrollment Study schedule (practical, reasonable) Study duration Non-routine care items Imaging Pharmacy Lab/specimens Resources (study coordinator, data manager, 24/7) Adequate staffing Training requirements Special vendor requirements
35
36 Budget Billing Coverage Analysis Spreadsheet from CRMS Deemed and Qualified Epic Billing calendar Funding source (federal or industry) Consistent approach Ensure start up fees are sufficient and invoiced Standardized fees Screen fails Monitoring visits Monthly invoicing IDS CTRC
37
38 CTA Submit CTA to OIC via CRMS, direct link to ALICE Complete review request form (RRF) Contract manager assigned Only the assigned contract manager negotiates the CTA Open communication with your contract manager The CTA can be negotiated while you negotiate your budget Once budget has been finalized with sponsor we can execute the CTA
39
40 IRB Submit when you are sure the PI wants to participate UNC local IRB or Central IRB ICF and contract must be consistent in respect to subject injury, stipends and what has been promised for free to the subjects
41
42 CTA and IRB IRB Approval ICF and CTA must be consistent OCT will check but you should also check If inconsistent the ICF will need to be revised
43
44 Ramses eipf Internal budget Need an account Set up after all compliance checks are completed by OCT Sent to OSR for final PS project ID assignment COI Individual Institutional
45 CTA Executed Study Information is pushed to EPIC via CRMS Account Number Assigned Conflict of Interest eform completed eipf completed in Ramses CTA Executed CTA/ICF checked for Consistency Site Initiation Visit Billing Calendar Built in Epic Prepare for/enroll Subjects Enrollment Complete Study Closure
46 Study Start Up When can I enroll! Its been months and I am already tired
47 Mornings in the Regulatory World
48 What Types of Trials Should Meet GCP Guidelines? FDA Regulated Trials Federally funded (NIH) Trials Requirement as of January, 2017 A quality research site complies with the ICH Good Clinical Practice guidelines, the accepted international ethical and scientific quality standards for designing, conducting, recording, and reporting trials involving human participants. American Society of Clinical Oncology Statement on Minimum Standards and Exemplary Attributes of Clinical Trial Sites; R. Zion et al; Journal of Clinical Oncology; April 7, 2008
49 What are Essential Documents? ICH defines Essential Documents as: The documents which individually and collectively permit the evaluation of the conduct of a trial and the quality of the data produced (ICH GCP E6 (R2) 8.1)
50 BEFORE STUDY IS INITIATED: Investigative Site Sponsor/Funding Agency
51 Documentation for Investigators and Sub- Investigators Curriculum Vitae Licensure Certifications Documents qualifications and eligibility to conduct trial Documents eligibility to provide medical supervision of subjects Documents qualifications to perform tasks as delegated GCP 2.8, 4.1.1, 4.1.5
52 AND MORE APPROVAL DOCUMENTS AGREEMENTS Institutional Review Board Regulatory Authorities Protocol Review Committee Institutional Biosafety Committee Scientific Review Committee Site and Sponsor/Funding Agency Site and CRO Financial Aspects Disclosure Forms (FDA) GCP 3.4, 4.5.1, 8.2.4, 8.2.9
53 AND MORE Normal Ranges Lab Info CLIA CAP CV of Medical Director GCP
54 JUST A FEW MORE Investigational Product Shipping and Accountability Records Applicable for both Drugs and Devices Procedures for Decoding Blinded Trials used in case of emergency doesn t break blind for others Study Initiation Report Document questions asked during SIV! GCP , , , ,
55 Include: LOGS DELEGATION OF AUTHORITY LOG / SIGNATURE SHEET SCREENING LOG SUBJECT ENROLL- MENT LOG SUBJECT ID CODE LIST TRAINING LOGS Protocol IB Equipment CRF Completion / Correction OTHER LOGS GCP 4.1.5, 4.2.4, ,
56 Study Start Up SIV Site Initiation Visit Study supplies CRMS Clinical Research Management System (OnCore for Oncology studies) Epic IDS Investigational Drug Services at UNC Healthcare Subject binders Source documents Study visit checklist
57 Study Conduct Enroll your first subject Inclusion/exclusion criteria ICF Documentation of the informed consent process Maintenance of Essential Documents
58 Documents updated during the study UPDATE Laboratory Accreditations (CLIA/CAP) 1572 /Investigator Agreement Only required by FDA if a new protocol is added to the IND and the Investigator is participating OR a new investigator is added Investigator s Brochures Normal values to lab ranges GCP , 8.3.1, 8.3.6
59 Update IRB renewals / modifications Regulatory Authorities Biosafety Committee Protocol Review Committee CV s / Licensures / Certifications for New Investigators GCP
60 INCLUDE RELEVANT COMMUNICATIO NS Letters Memos to File Meeting Notes Telephone Calls GCP
61 Ongoing conduct of study Study visit checklists Case report forms Epic Billing review Investigational product accountability SAE/AE reporting Monitor Access Annual IRB renewal Amendments Modifications Deviations
62 STUDY COMPLETION / CLOSE OUT All study subjects complete Data lock / IRB closure Logs Investigational Product Accountability Subject Identification Code Final Close-out monitoring report Includes where site documents will be stored Clinical Study Report Pack up the records Pat yourself on the back
63 Record Retention Requirements Depends on the Type of Trial FDA: 21CFR (IND) OR 21CFR (IDE) Contracts with Funding Source Institutional Policies: (see Section 6 Grants and Research Records) Pediatric Studies UNC Healthcare Policy? GCP
64 Audits FDA or Sponsor Who do you call? Hint its not Ghost Busters!
65 Inspections and Essential Documents Sponsors and other regulatory agencies look to these documents as part of their processes to confirm the validity of the conduct of the trial and the data collected
66 TAKE AWAY POINTS Organized Consistent
67
68 ENTER NEXT Training November XX, 2017, 12 noon 1:30pm Brinkhous-Bullitt Bldg, Room 219
Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents
Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time
More informationESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL
Assemble Essential Documents in Trial Master File (TMF) Appendix 1 ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL 8.2 Before the Clinical Phase of the Trial Commences During this planning stage
More informationRegulatory Binder Guidance
Regulatory Binder Guidance What is the purpose of a regulatory binder? Achieve and maintain regulatory compliance Ensure protection of human subjects and high standards of research Guidance for organization
More informationSTANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down
Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 1. BACKGROUND 17. Study Close Down According to ICH Good Clinical Practice (GCP)
More informationPOST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)
POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) Purpose: Investigators who initiate and submit an IND application to the FDA assume the responsibilities of both the
More informationOffice Of Clinical Trials. Christine Nelson, RN, BSN, MBA, CCRC
Office Of Clinical Trials Christine Nelson, RN, BSN, MBA, CCRC OCT Mission Statement The mission of the Office of Clinical Trials (OCT) is to serve the Carolina research community by improving the quality
More informationCompliance and Quality Monitoring: What, Why, When, and How
Compliance and Quality Monitoring: What, Why, When, and How Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Research Institute, University
More informationRegulatory Binder: Set-up and Maintenance
Regulatory Binder: Set-up and Maintenance Introduction Federal and state regulations, institutional policy, and good clinical and research practices require investigators to maintain documents related
More informationSource Documents and Regulatory Binders October 6, 2016
Source Documents and Regulatory Binders October 6, 2016 Lisa Wilson, Regulatory Lead, Clinical Trials Office and Mark Alger, CRC, Clinical Trials Office Essential Documents AKA: the stuff in the Reg Binder
More informationRegulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1
Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1 Phone: 650.691.4400 Fax: 650.691.4410 Email: regulatory.ccsainc.com COMPLIANCE & STANDARDIZATION Rationale for Revision of
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More informationFDA Sponsor and Investigator Responsibility Checklist
FDA Sponsor and Investigator Responsibility Checklist Principal Investigator: Study Name: CPHS #: IND/IDE #: Name of IND/IDE holder: The following checklist is created based on the Sponsor and Investigator
More informationRegulatory Document Guidelines for DMID Clinical Studies. Version Oct-2005
Regulatory Document Guidelines for DMID Clinical Studies Version 3.0-5-Oct-2005 1 Regulatory File Document Guidelines Purpose: To aid DMID supported Investigators in establishing a file of essential documents
More informationClinical Trial Basics:
Clinical Trial Basics: Components and Responsibilities Pre-Award Aida Nana Ama Manu, Project Coordinator Four Main Components Non-Disclosure Agreements Institutional Review Board Application Clinical Trial
More informationMulti-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18
Multi-Site Coordination Process Drafted by: Ester Dimayuga Page 1 of 18 MULTI-SITE COORDIATIO (MSC) REGULATOR PROCESS CTO-Regulatory notifies MSC of trial with UMCC as coordinating center MSC prepares
More informationHuman Research Protection Program Policy
Adopted: 11/2005 Revised: 03/2014 Page: 1 of 6 RIGHTS AND RESPONSIBILITIES OF PRINCIPAL INVESTIGATORS IN HUMAN SUBJECTS RESEARCH POLICY Each research study will have a Principal Investigator (PI) and may
More informationESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL
ESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL THIS INFORMATION SHEET (ISR-RG-014) HAS BEEN TAKEN DIRECTLY FROM THE ICH- GUIDELINE* WITH ADDITIONAL COMMENTS ADDED BY THE RESEARCH GOVERNANCE
More informationGuidelines for Setting Up a Regulatory Binder
Guidelines for Setting Up a Regulatory Binder Prepare for an audit Georgamaly Estronza, MS UPR - Medical Sciences Campus IRB Administrator - Compliance Officer Email: georgamaly.estronza@upr.edu Introduction
More informationInvestigational New Drug Development Steps for CRCs
Investigational New Drug Development Steps for CRCs Natalie Nardone, PhD Program Manager, Department of Medicine CRC Instructor, Office of Clinical Research Contact: natalie.nardone@ucsf.edu Learning Objectives
More informationSTANDARD OPERATING PROCEDURE. STH Researcher. Investigator Site File
Research Department STANDARD OPERATING PROCEDURE STH Researcher SOP History CSUH 00/016 SOP Number A116 Created STH Research Department (TL) Reviewed by STH Research Department (AL) 06 August 2009 Superseded
More informationVCU Faculty Held IND and IDE Procedure Handbook
VCU Faculty Held IND and IDE Procedure Handbook Contents A. Introduction... 3 B. Purpose of Institutional Oversight... 3 C. Applicability... 4 D. University Oversight of Clinical Investigations Being Conducted
More informationInvestigator Site File Index (CTIMP)
Study Title: Site Name/Number: REC Reference Number: Sponsor Reference Number: EudraCT Number: 1. Protocol Current version plus all previous versions (or provide file note to detail location of previous
More informationELEMENTS OF A DATA MONITORING PLAN
ELEMENTS OF A DATA MONITORING PLAN Definitions Data Monitoring: The regular evaluation of data and documentation collected during a study to ensure both adherence to the approved investigative plan and
More informationObjectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder
Essential Documents: Maintaining the Site's Regulatory Binder How to Manage the Essential Documents for the Investigator and Study Site Objectives Describe the importance of maintaining the Regulatory
More information1. POLICY STATEMENT: 2. BACKGROUND:
POLICY #: RCO-201 Page: 1 of 5 1. POLICY STATEMENT: All Food and Drug Administration (FDA) regulated research conducted under an Investigational New Drug Application (IND) and managed within DF/HCC requires
More informationQuality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework
1 Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework Mandy Morneault Research Compliance Monitor University of Washington Institute of Translational Health
More informationSource And Regulatory Documentation for DMID Clinical Studies
Source And Regulatory Documentation for DMID Clinical Studies Walt Jones RN, MPH Nurse Consultant Clinical Monitoring Coordinator OCRA, DMID, NIAID November, 2007 Source Data Defined All information in
More informationRESEARCH AUDIT Standard Operating Procedure
Reference Number: UHB 236 Version Number: 2 Date of Next Review: 17 th Oct 2020 Previous Trust/LHB Reference Number: N/A RESEARCH AUDIT Standard Operating Procedure Introduction and Aim As a legal Sponsor
More information4.2. Investigator Regulatory Binder: Files, usually a binder, maintained by the investigator at the investigative site.
POLICY #: RCO-203 Page: 1 of 7 1. POLICY STATEMENT: Essential regulatory documents will be on maintained for research sponsored by or conducted at Dana-Farber/Harvard Cancer Center (DF/HCC) to assure compliance
More informationImplementing Good Clinical Practice at an Academic Research Institution
Implementing Good Clinical Practice at an Academic Research Institution Maintaining Essential Documents Partners Human Research Quality Improvement (QI) Program Stephen W. Hayes Outline Significance of
More informationInvestigator Site File Index (Medical Devices)
Study Title: Site Name/Number: REC Reference Number: Sponsor Reference Number: EudraCT Number: 1. Protocol (Clinical Investigation Plan) Current version plus all previous versions (or provide file note
More informationSponsor-Investigator Responsibilities In Clinical Trials
In Clinical Trials Margaret Huber, RN, BSN, CHRC Compliance Manager The lecturer has no conflicts for this presentation 9/23/2015 Objectives Define terms sponsor, investigator, and sponsor-investigator.
More informationAudit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.
Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,
More informationIDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES
IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES Karen Weaver Epstein, Becker & Green Health Care & Life Sciences Practice APPLICABLE REGULATIONS 21 CFR 312
More informationROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016
UCLA CTSI WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016 Objectives Define the sponsor of a clinical trial and learn
More informationStudy Files and Filing
Study Files and Filing The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.ths.nhs.uk/departments/research/research.htm
More informationSELF-ASSESSMENT CHECKLIST
SELF-ASSESSMENT CHECKLIST SECTION 1: REGULATORY DOCUMENTATION Staff Documentation 1. Are all versions of the IRB approved protocol on file (including most recent)? 2. Are there CVs/biosketches of PI, Co-Is,
More informationClinical Research with Drugs/Biologics and Devices & Good Clinical Practices
Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices Jason Jobson, BLS, CCRP Research Compliance Officer Oklahoma City VA Medical Center October 2017 Goals Investigational New Drug
More informationROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Investigational
More informationDemystifying Audits. Audits and Audit Preparation 5/23/2016. What is an Audit?
Demystifying Audits Darlene Kitterman, MBA Director, Investigator Support & Integration Services OCTRI May 26, 2016 Audits and Audit Preparation What is an Audit? A systematic and independent examination
More informationand Study Initiation
10 STUDY SPECIFIC PRE-IMPLEMENTATION, SITE ACTIVATION AND STUDY INITIATION... 2 10.1 Clinical Trials Agreement... 4 10.2 Study Product Acquisition and Shipment to Sites... 5 10.3 Study-specific Preparatory,
More informationand Study Initiation
10 STUDY SPECIFIC PRE-IMPLEMENTATION, SITE ACTIVATION AND STUDY INITIATION... 2 10.1 Clinical Trials Agreement... 4 10.2 Study Product Acquisition and Shipment to Sites... 5 10.3 Study-specific Preparatory,
More informationQuality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits
Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick
More informationCompliance Program Guidance Manuals (CPGMs) -1-
Inspector s Preparation for a CI Inspection: FDA Compliance Program & the Records Inventory Jean Toth-Allen, Ph.D. APEC GCP Inspection Workshop May 28, 2008 Compliance Program Guidance Manuals (CPGMs)
More informationClinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014
Clinical Trials and the Code of Federal Regulations Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 The Development of Regulations 1906: Food and Drugs Act
More informationIBC SERVICES SUBMISSION REQUIREMENTS Part B: Review of Protocol
IBC SERVICES SUBMISSION REQUIREMENTS Part B: Review of Protocol Use this checklist to assemble your request for your institution s IBC to review a specific protocol. If WIRB does not already administer
More information\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management
Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles
More informationLOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office
LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE Loughborough University (LU) Research Office SOP 1024 LU Study Closedown and End of Study Reporting for NHS Research Sponsored by Loughborough
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
POLICY #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities
More informationUC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities
UC Irvine s Clinical Research Coordinator Certification Preparation Series PI Roles and Responsibilities BEVERLY ALGER, CCRP, CHRC Research Compliance Officer Office of Research Compliance November 2016
More informationFDA Audit Preparation
Duke University Office of Audit, Risk and Compliance (OARC) FDA Audit Preparation Margaret M. Groves, JD, CRA, CCRP, CHRC Associate Compliance Officer, Research Compliance Assurance (RCA) External audits
More informationIRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010
IRB-GCP and Timelines Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October 11-14 th, 2010 1 Factors that affect Timelines Finalized Protocol Finalized
More informationORC Sponsor-Investigator IDE Checklist
A sponsor-investigator assumes BOTH investigator and sponsor responsibilities as outlined in the FDA Code of Federal Regulations 21CFR812. This means that such investigators have additional responsibilities.
More informationConducted Under an IND to Support a
Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.
More informationClinical Trials Series Part II
Clinical Trials Series Part II Agenda Recap December Presentation J. Schmelz Example: New CT from HSC Investigator Non Cancer Clinical Trial J. Bates, P. Miranda Example: New CT from External Entity Non
More information1 The Clinical Research Coordinator (CRC)... 1
TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More informationIntroduction to Clinical Research
Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that
More informationInvestigator-Initiated INDs
Investigator-Initiated INDs Marjorie Small, RN, CCRC Office of Clinical Research 23 May 2011 PPHS/IRB Research Grand Rounds Outline of Presentation I. What is an IND? II. Code of Federal Regulations III.
More informationLouise Brook Clinical Trials Quality Monitor. Date
Details: Author: Louise Brook Clinical Trials Quality Monitor SOP Pages: 12 Version No. of replaced SOP: Effective date of replaced SOP: NA NA Approval: Version No: of the SOP being approved. Name of person
More informationThe Right Prescription for Working with Investigational Drug Service at BMC
The Right Prescription for Working with Investigational Drug Service at BMC Andrew Schoch Pharmacy Intern Northeastern University Class of 2010 Hyeseon Hong, Pharm.D. IDS Pharmacy Manager What is Investigational
More informationInvestigator s Responsibility
Investigator s Responsibility Introduction Investigator s Qualifications Clinical Trial Agreement Adequate Resources Medical Care of Trial Subjects Communication with IRB/IEC Study Initiation Patient Recruitment
More informationSponsor/Investigator Responsibilities
Sponsor/Investigator Responsibilities Marian Serge, RN Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health Food and Drug Administration Marian.Serge@fda.hhs.gov
More informationPreparing for Close-Out of Studies and Sites
Preparing for Close-Out of Studies and Sites Presented by: Christie Thomas, MPH, CCRA Matthew Wright, BS, CCRP Dikla Blumberg, PhD CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced
More informationResearch Study Close-down and Archiving Procedures
Title: Research Study Close-down and Archiving Procedures Outcome Statement: To inform researchers of the process for closing down research studies, retaining and storing research materials in the Trust.
More informationI. Purpose. II. Definitions. Last Approval Date
Investigational Drugs and Biologics Page 1 of 13 I. Purpose The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics
More informationDANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR CLINICAL RESEARCH
DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR CLINICAL RESEARCH TITLE: SOP #: QA-706 Page: 1 of 7 Applicable Regulations & Guidelines: 21 CFR 312.60 General Responsibilities of
More informationUniversity of California, Irvine Human Research Protections Standard Operating Policies and Procedures
University of California, Irvine Human Research Protections Standard Operating Policies and Procedures Policy Number: 41 Title: Investigational Drugs, Agents, and Biologics Date of Last of Revision: 07/28/2006;
More informationFDA Audit Preparation
Duke University Ethics and Compliance Office FDA Audit Preparation Margaret M. Groves, JD, CRA, CCRP, CHRC Director, CTQA Agenda External audits Best practices to get ready for audits 2 External Audits
More informationNational Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services
National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services The Division of Microbiology and Infectious Diseases (DMID), National Institute
More informationUS Special Operations Command Human Research Protection Office
S- US Special Operations Command Human Research Protection Office Human Research Protocol Submission Form for Headquarters Level Administrative Review of Extramural* Research PURPOSE: All United States
More informationClinical Evaluation Phases 1,2,3,4
Clinical Evaluation Phases 1,2,3,4 Matt Laurens, MD MPH Associate Professor of Pediatrics Center for Vaccine Development Institute for Global Health University of Maryland School of Medicine February 1,
More informationObtaining Pre-Study Approvals for Clinical Trials K-30 Module 5 Navigating the Pre-Award Process
Obtaining Pre-Study Approvals for Clinical Trials K-30 Module 5 Navigating the Pre-Award Process Helene Orescan, J.D. Bishoy Anastasi, MBA, CCRP David Geffen School of Medicine at UCLA Industry Sponsored
More informationSTANDARD OPERATING PROCEDURE SOP 410. Set up and Initiation of an Investigator Site
STANDARD OPERATING PROCEDURE SOP 410 Set up and Initiation of an Investigator Site Version 1.2 Version date 4.01.2017 Effective date 5.07.2017 Number of pages 13 Review date July 2019 Author Role NNUH
More informationRisk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight
Risk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight Lisa Marie Saldanha Senior Director & Head of Operations Real World Insights Asia Singapore Research & Ethics Conference
More informationGCP INSPECTION FINDINGS Singapore Research Ethics Conference 2018
1 GCP INSPECTION FINDINGS Singapore Research Ethics Conference 2018 Sumitra Sachidanandan GCP Inspection Consultant Clinical Trials Branch Health Products Regulation Group Health Sciences Authority Singapore
More informationFRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up?
FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up? The following framework of characteristics focuses on attributes that are within the control of investigators and their
More informationOCTC 2012 CRO Selection
OCTC 2012 CRO Selection Colin Macaulay Viron Therapeutics Inc. 15 Nov 2012 Viron Therapeutics Inc. Virtual Biotech Company (6) Phase 2a (48 pt) clinical trial in acute coronary syndrome (ACS) completed
More informationCompassionate Use Navigator Information for Physicians
Compassionate Use Navigator Information for Physicians Contact: Elena Gerasimov, Program Director, Elena@kidsvcancer.org. As a physician, you must have wished there would be more treatment options for
More informationAnnex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO
23 August 2017 EMA/431267/2016 Annex IV to guidance for the conduct of good clinical practice inspections sponsor Adopted by GCP Inspectors Working Group (GCP IWG) 29 November 2017 Keywords GCP inspection,
More informationGood Clinical Practice Compliance
Good Clinical Practice Compliance Pharmaceutical Regulatory & Compliance Congress Greg Levine LLP Agenda? GCP compliance rules What is the law? What other (non-binding) standards apply? What are the unwritten
More informationHuman Research Protection Program Policy
Page 1 of 5 REVIEW OF INVESTIGATIONAL NEW DRUG (IND)/INVESTIGATIONAL DEVICE EXEMPTION (IDE) RESEARCH IN HUMAN SUBJECTS RESEARCH POLICY It is the policy of the University of Cincinnati that studies involving
More informationClinicalTrials.gov REGISTRATION REQUIREMENTS
ClinicalTrials.gov REGISTRATION REQUIREMENTS Background: What is it? ClinicalTrials.gov is a public registry that provides easy access to information on clinical studies, both clinical trials and observational
More informationEVENT TYPE TIMING REQUIRED FORM
Reportable Events EVENT TYPE TIMING REQUIRED FORM Unanticipated Problem or Adverse Event 10 days Event Reporting Form Death (related) 10 days Event Reporting Form Death (not related) Renewal Summary with
More informationHub Performance Assessment
Hub Performance Assessment Hub complex performance assessment will be assessed with a standardized report card mechanism. The report card draws on data quality reports, enrollment reports, and monitoring
More informationStandard Operating Procedures (SOPs)
Organizational Strategies for Clinical Trials Standard Operating Procedures (SOPs) SUSAN JACKSON, MPA UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL CENTER FOR GASTROINTESTINAL BIOLOGY AND DISEASE UNC CENTER
More informationStandard Operating Procedure
Standard Operating Procedure Number: UM/UoM TMF/SOP08/6.0 Title: The Creation and Maintenance of Trial Master Files and Essential Documentation Version: 6.0 () Effective Date: Author: Mrs Catherine Barrow
More informationManaging a Research Team. Mandy Morneault Manager, Research Coordinator Core ITHS Clinical Services
Managing a Research Team Mandy Morneault Manager, Research Coordinator Core ITHS Clinical Services vicka@uw.edu, 206-355-5210 PI responsibilities and organizing a research team Hiring research staff Effective
More informationGood Clinical Practice. Martin Rose, MD, JD February 8, 2018 ASQ
Good Clinical Practice Martin Rose, MD, JD February 8, 2018 ASQ Disclaimer The views expressed in this presentation are those of the presenter and do not necessarily represent the official position of
More informationTrial Master File. SOP No. SOP 7
Trial Master File SOP Title Trial Master File SOP No. SOP 7 Author Consultation Departments Date approved Julia Farmery Lincolnshire Clinical Research Facility, Research and Development, Trust consultants
More informationDocument Title: Site Recruitment and Initiation for Papworth Sponsored Studies
Document Title: Site Recruitment and Initiation for Papworth Sponsored Studies Document Number: SOP015 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For
More informationMaintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success. Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist
Maintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist Agenda How an investigator should prepare and submit
More information1.0 INTRODUCTION AND OVERVIEW
Table of Contents 1.0 INTRODUCTION AND OVERVIEW... 3 2.0 DEFINITIONS... 4 3.0 OVERSIGHT AND ORGANIZATION... 5 3.1 CLINICAL RESEARCH OVERSIGHT COMMITTEE (CROC)... 5 3.2 CLINICAL RESEARCH SUPPORT (CRS)...
More informationEffectively Preparing for and Responding to an FDA Audit: The Research Team s Perspective
1 Effectively Preparing for and Responding to an FDA Audit: The Research Team s Perspective Kate-Louise Gottfried, JD, MSPH, Senior Director Stephanie C. Guzik, RN, BSN, MBA, Assistant Director Research
More informationStudy Start-Up SS STANDARD OPERATING PROCEDURE FOR Investigator Selection
Effective date of version: April 01, 2012 Study Start-Up SS 202.00 STANDARD OPERATING PROCEDURE FOR Investigator Selection Approval: Nancy M. Paris, MS, FACHE President and CEO 08 March 2012 (Signature
More informationStandard Operating Procedures (SOP) Research and Development Office
Standard Operating Procedures (SOP) Research and Development Office Title of SOP: Essential Documentation and Creation and Maintenance of Trial Master File SOP Number: 13 Version Number: 2.0 Supercedes:
More informationGCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:
GCP Refresher and GCP/GCDMP Trends Presented by: in the CTN Denise King, MS, RD, CCRA & Lauren Yesko, BS CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced by: CTN Training This training
More informationRegulatory Visits, Audits and Investigations
Regulatory Visits, Audits and Investigations The Role of the Compliance Officer Carole A. Klove, JD, RN, CHRC Juliann Tenney, JD, CHRC Welcome! The content of this presentation does not necessarily represent
More informationShow Me Your Docs! A REVIEW OF UNIVERSITY OF PITTSBURGH GUIDELINE: STUDY DOCUMENTATION FOR FDA REGULATED RESEARCH
Show Me Your Docs! A REVIEW OF UNIVERSITY OF PITTSBURGH GUIDELINE: STUDY DOCUMENTATION FOR FDA REGULATED RESEARCH Speakers Kelly Dornin-Koss, MPPM, RN, CCRC Director Education and Compliance for Human
More information